Rasagiline is an approved anti-parkinson drug in Europe and Israel. The present invention describes in-vivo experiments demonstrating the improvement in function of hypoperfused as well as normal kidneys pretreated with Rasagiline and its derivatives. Rasagiline derivatives produce significant diuretic and natriuretic responses in association with increased GFR in rats with CHF as well as induce diuretic and natriuretic responses accompanied by improved GFR in the ischemic kidney. It is proposed that this derivative can be used for the treatment of acute and chronic kidney failure.
1586128594.png)